Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.
The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Biogen’s litifilimab has received Breakthrough Therapy Designation from the US FDA to treat cutaneous lupus erythematosus ...
Flow Space on MSN
‘I Thought Feeling This Bad Was Normal': The Overlooked Signs Your Lupus Needs More Attention
There are a few to keep in mind.
Subcutaneous anifrolumab is superior to placebo in multiple systemic lupus erythematosus disease activity measures at 52 ...
Today, the Lupus Research Alliance, the world's largest private funder of lupus research, announced the 2025 Global Team ...
Flow Space on MSN
Living with lupus in your 30s, 40s & 50s: Treatment questions every woman should be asking
You've changed. And your care plan should too.
The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...
Lupus is an unpredictable and misunderstood autoimmune disease. It is difficult to diagnose, hard to live with, and a challenge to treat. Lupus has a range of symptoms, and strikes without warning.
Investigators compared the risk of cancer onset in patients with lupus nephritis treated with calcineurin inhibitors vs ...
A treatment that restores normal kidney function in almost half of patients with lupus nephritis has been approved by the National Institute for Health and Care Excellence (NICE). Obinutuzumab ...
Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results